Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly

Chinese Journal of Pathology

Volumn 40, Issue 9, 2011, Pages 616-621

  Xu, Fang Ping ^a   Liu, Yan Hui ^a   Zhuang, Heng Guo ^a   Luo, Dong Ian ^a   Li, Li ^a   Zhang, Fen ^a   Luo, Xin Lan ^a   Du, Xin ^a   Li, Wen Yu ^a   Chen, Qi ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Aged; In situ hybridization; Lymphoma, B cell; Lymphoma, large cell, diffuse

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD30 ANTIGEN; CD79 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR-4; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

AGED; ARTICLE; BLOOD; CANCER STAGING; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; ISOLATION AND PURIFICATION; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; VIROLOGY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTIGENS, CD30; ANTIGENS, CD79; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON REGULATORY FACTORS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 80053518691     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2011.09.009     Document Type: Article

References (17)

1. Fisher R, Miller T, O'Connor O. Diffuse aggressive lymphoma//Broudy V, Berliner N, Larson R, et al. Hematology 2004. American Society of Hematology Education Program Book. Amsterdam; Elsevier Health Sciences, 2004:221-236.
2. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV + B-cell lymphoproliferative disorders; a clinicopathologic study of 22 patients. Am J Surg Pathol, 2003, 27(1):16-26. (Pubitemid 36014895)
3. Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma//Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours. WHO classification of tumours of haematopietic and lymphoid tissues. Lyon: I ARC, 2008:243-244.
4. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res, 2007, 13(17):5124-5132. (Pubitemid 47502080)
5. Wong HH, Wang J. Epstein-Barr vims positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma, 2009, 50(50):335-340.
6. Asano N, Yamamoto K, Tamaru J, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood, 2009, 113(12):2629-2636.
7. Ouyang Q, Wagner WM, Walter S, et al. An age-related increase in the number of CD8 + T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev, 2003, 124(4):477-485. (Pubitemid 36519208)
8. Yasunaga JI, Sakai T, Nosaka K, et al. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. Blood, 2001, 97(10):3177-3183.
9. Harada S, Kamata Y, Ishii Y, et al. Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immunol, 2004, 11(1):123-130. (Pubitemid 38090665)
10. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med, 2004, 350(13):1328-1337. (Pubitemid 38375368)
11. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood, 2007, 110(3):972-978. (Pubitemid 47267436)
12. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma; a population-based study. Blood, 2005, 106(7):2444-2451. (Pubitemid 41510819)
13. Liu YH, Xu FP, Zhuang HG, et al. Clinicopathological significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 2008, 39(6):875-884.
14. Yoshino T, Nakamura S, Matsuno Y, et al. Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. Cancer Sci, 2006, 97(2):163-166. (Pubitemid 43379485)
15. Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood, 2004, 104(104):243-249. (Pubitemid 38879864)
16. Liu TY, Wu SJ, Huang MH, et al. EBV-positive Hodgkin lymphoma is associated with suppression of p21cipl/wafl and a worse prognosis. Mol Cancer, 2010, 9:32.
17. Sónchez-Beato M, Sdnchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood, 2003, 101(101):1220-1235. (Pubitemid 36182489)